Fibrillatory Factor in Ventricular Tachycardia

Status Not yet recruiting

Clinical Trial Summary

This study involves recording electrical signals inside the heart during an ablation procedure. It is thought that by studying these electrical signals in detail the investigators may be able to better identify and treat patients at risk of Ventricular Tachycardia (VT).

VT is where the lower chambers (ventricles) of your heart beat fast and this condition can be life-threatening. An ablation procedure is performed in patients who have VT despite the best treatment available with tablets.

Cardiac ablation involves interrupting the abnormal electrical signals, which cause VT, by applying a type of electrical energy through a catheter. An important part of the ablation procedure is the identification of the exact part of the heart muscle responsible for causing the VT. This typically involves sampling the electrical signals in lots of different areas of the heart, which allows the construction of computer generated 3 dimensional pictures of the structure and the electrical circuits inside the ventricle. Recent research has identified a new method to interpret these electrical signals (called Fibrillatory Factor - FF), which may allow better identification of the area within the ventricle that should be ablated.

A standard VT ablation will often involve us controlling the heart-beat by pacing the heart through 1 of the investigators catheters within the heart. The electrical response to pacing at different heart rates can often provide your doctor with information to help the ablation. This study will involve an additional period of pacing at different heart rates, during which the electrical response is measured in different areas around the ventricle. This will allow us to calculate areas of the ventricle, which the investigators new measure FF would predict to be the source of the VT. In the future this may then allow us to better identify patients who are at risk of VT, and to better locate the area that needs to be ablated.

Clinical Trial Description

n/a

Study Design

Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01974908
Study type	Interventional
Source	Guy's and St Thomas' NHS Foundation Trust
Contact	Jaswinder Gill, MD
Phone	+44 2071887188
Email	jaswinder.gill@gstt.nhs.uk
Status	Not yet recruiting
Phase	N/A
Start date	November 2013

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT03453645` - Modification of Rhythmic Risk Assessment by Ventricular Tachycardia Ablation
Completed	`NCT05791032` - Sub Chronic Evaluation for ATP With an Extravascular Placed ICD Lead (STEP ICD) Study	N/A
Completed	`NCT05970120` - A Study of Intracardiac Ultrasound With the NUVISION NAV Ultrasound Catheter	N/A
Completed	`NCT04011631` - Evaluation of the iD-SystemTM, One-Handed Disposable Internal Defibrillation System.	N/A
Recruiting	`NCT03536052` - Ablation at Virtual-hEart pRedicted Targets for VT	N/A
Not yet recruiting	`NCT06063811` - Ventricular Tachycardia Ablation in LVAD Patients
Enrolling by invitation	`NCT02962076` - Study of Cardiac PET/CT Imaging to Guide Ablation Treatment of Ventricular Tachycardia	Early Phase 1
Not yet recruiting	`NCT02784912` - Biomarkers in Risk Stratification of Sustainted Ventricular Tachycardia or Electrical Storm After Ablation	N/A
Completed	`NCT01791543` - Intramural Needle Ablation for Ablation of Recurrent Ventricular Tachycardia	N/A
Terminated	`NCT02891863` - Low Energy Therapy to Convert Ventricular Tachycardias	Phase 0
Terminated	`NCT01546207` - Stepwise Approach To sUbstrate Modification for Ventricular Tachycardia	N/A
Completed	`NCT01294267` - Percutaneous Hemodynamic Support With Impella 2.5 During Scar-related Ventricular Tachycardia Ablation	N/A
Terminated	`NCT00383799` - Iv Amiodarone Versus Iv Procainamide to Treat Haemodynamically Well Tolerated Ventricular Tachycardia	Phase 4
Completed	`NCT04884100` - enHEART - Exploring Full Content of Optical Signals to Enhance Cardiac Arrhythmia Screening	N/A
Completed	`NCT04642963` - Stereotactic Management of Arrhythmia - Radiosurgery in Treatment of Ventricular Tachycardia	N/A
Recruiting	`NCT05377216` - Characterization of Cardiac Electrophysiological Effects of Autonomic Neuromodulation	Early Phase 1
Not yet recruiting	`NCT04990089` - VIVO European Observational Registry
Completed	`NCT04065893` - Impact of Catheter Ablation of Ventricular Arrhythmias on Suboptimal Biventricular Pacing in Cardiac Resynchronization Therapy
Recruiting	`NCT03631303` - Post-Extrasystolic Potentiation as a Predictor of Ventricular Arrhythmias
Recruiting	`NCT03611465` - Creation of a Pace-mapping Atlas on Healthy and Pathological Hearts	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.